Title : Olaparib Combined With Dacomitinib in Osimertinib-Resistant Brain and Leptomeningeal Metastases From Non-Small Cell Lung Cancer: A Case Report and Systematic Review.

Pub. Date : 2022

PMID : 35494030






2 Functional Relationships(s)
Download
Sentence
Compound Name
Protein Name
Organism
1 For those patients with EGFR mutations, osimertinib, a third-generation tyrosine kinase inhibitor (TKI), is the first choice of treatment. osimertinib epidermal growth factor receptor Homo sapiens
2 This 55-year-old male patient was found to have a pL858R mutation on EGFR exon 21 combined with TP53 and ERBB2 mutations after developing drug resistance to osimertinib treatment. osimertinib epidermal growth factor receptor Homo sapiens